0
Original Contribution |

Investigation of C9orf72 in 4 Neurodegenerative Disorders

Zhengrui Xi, PhD; Lorne Zinman, MD; Yakov Grinberg, PhD; Danielle Moreno, BSc; Christine Sato, MSc; Juan M. Bilbao, MD; Mahdi Ghani, MD; Isabel Hernández, MD; Agustín Ruiz, MD, PhD; Mercè Boada, MD, PhD; Francisco J. Morón, PhD; Anthony E. Lang, MD; Connie Marras, MD, PhD; Amalia Bruni, MD; Rosanna Colao, MD; Raffaele G. Maletta, MD; Gianfranco Puccio, MD; Innocenzo Rainero, MD, PhD; Lorenzo Pinessi, MD; Daniela Galimberti, PhD; Karen E. Morrison, PhD; Catriona Moorby, BSc; Joanne D. Stockton, BSc; Mario Masellis, MD; Sandra E. Black, MD; Lili-Naz Hazrati, MD; Yan Liang, MD; Jan van Haersma de With, BSc; Luis Fornazzari, MD; Roque Villagra, MD; Ricardo Rojas-Garcia, MD, PhD; Jordi Clarimón, PhD; Richard Mayeux, MD; Janice Robertson, PhD; Peter St George-Hyslop, MD, FRCP(C); Ekaterina Rogaeva, PhD
Arch Neurol. 2012;69(12):1583-1590. doi:10.1001/archneurol.2012.2016.
Text Size: A A A
Published online

Objective  To estimate the allele frequency of C9orf72 (G4C2) repeats in amyotrophic lateral sclerosis (ALS), frontotemporal lobar degeneration (FTLD), Alzheimer disease (AD), and Parkinson disease (PD).

Design  The number of repeats was estimated by a 2-step genotyping strategy. For expansion carriers, we sequenced the repeat flanking regions and obtained APOE genotypes and MAPT H1/H2 haplotypes.

Setting  Hospitals specializing in neurodegenerative disorders.

Subjects  We analyzed 520 patients with FTLD, 389 patients with ALS, 424 patients with AD, 289 patients with PD, 602 controls, 18 families, and 29 patients with PD with the LRRK2 G2019S mutation.

Main Outcome Measure  The expansion frequency.

Results  Based on a prior cutoff (>30 repeats), the expansion was detected in 9.3% of patients with ALS, 5.2% of patients with FTLD, and 0.7% of patients with PD but not in controls or patients with AD. It was significantly associated with family history of ALS or FTLD and age at onset of FTLD. Phenotype variation (ALS vs FTLD) was not associated with MAPT, APOE, or variability in the repeat flanking regions. Two patients with PD were carriers of 39 and 32 repeats with questionable pathological significance, since the 39-repeat allele does not segregate with PD. No expansion or intermediate alleles (20-29 repeats) were found among the G2019S carriers and AD cases with TAR DNA-binding protein 43–positive inclusions. Surprisingly, the frequency of the 10-repeat allele was marginally increased in all 4 neurodegenerative diseases compared with controls, indicating the presence of an unknown risk variation in the C9orf72 locus.

Conclusions  The C9orf72 expansion is a common cause of ALS and FTLD, but not of AD or PD. Our study raises concern about a reliable cutoff for the pathological repeat number, which is important in the utility of genetic screening.

Figures in this Article

Sign In to Access Full Content

Don't have Access?

Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more

Subscribe for full-text access to content from 1998 forward and a host of useful features

Activate your current subscription (AMA members and current subscribers)

Purchase Online Access to this article for 24 hours

Figures

Place holder to copy figure label and caption
Grahic Jump Location

Figure 1. Families with the G4C2 repeat expansion. A, Frontotemporal lobar degeneration (FTLD) pedigree. B, Parkinson disease (PD) pedigree. Individual genotypes are shown beneath the corresponding diamond, including “at-risk” currently asymptomatic individuals. Arabic numbers indicate the repeat units (exp indicates expansion). The age at the time of examination is shown in the upper right corner. Age at onset is indicated for patients below the ID number. Sex of the family members is masked to protect privacy.

Place holder to copy figure label and caption
Grahic Jump Location

Figure 2. Comparison of the allele frequencies (repeats <30) between controls and cases in each disease cohort (AD indicates Alzheimer disease; ALS, amyotrophic lateral sclerosis; FTLD, frontotemporal lobar degeneration; and PD, Parkinson disease). Asterisks indicate a significant P value (nominal P < .05). In comparison with controls, there were 2 significant differences observed for the allele frequencies for the patients with FTLD, 4 for the patients with ALS, 2 for the patients with AD, and 2 for the patients with PD. A similar pattern was observed for all 4 diseases. The 5-repeat allele was significantly lower in FTLD, ALS, and PD than in controls and the 10-repeat allele in disease was significantly higher in all 4 disease groups than in controls. Expansion carriers were excluded from this analysis: controls, n = 602; FTLD, n = 488; ALS, n = 353; AD, n = 424; and PD, n = 287.

Tables

Interactive Graphics

Video

Country-Specific Mortality and Growth Failure in Infancy and Yound Children and Association With Material Stature

Use interactive graphics and maps to view and sort country-specific infant and early dhildhood mortality and growth failure data and their association with maternal

References

Correspondence

CME
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s “Cited By” API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Comment

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Topics
PubMed Articles
Jobs
JAMAevidence.com


Allele